Ruth F. Jarrett

Ruth F. Jarrett

Auto-generated profile, based on publicly available information

Ruth F. Jarrett

MRC-University of Glasgow Centre for Virus Research, Glasgow, UK

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Cell
Verified
Journal Article
Open access
EVErik Volz
Erik Volz
VHVerity Hill
Verity Hill
JMJohn T. McCrone
John T. McCrone
APAnna Price
Anna Price
DJDavid Jorgensen
David Jorgensen
OPOliver G. Pybus
Oliver G. Pybus
Global dispersal and increasing frequency of the SARS-CoV-2 Spike protein variant D614G are suggestive of a selective advantage but may also be due to a random founder effect. We investigate the hypothesis for positive selection of Spike D614G in the United Kingdom using more than 25,000 whole genome SARS-CoV-2 sequences. Despite the availability of a large data set, well represented by both Spike 614 variants, not all approaches showed a conclusive signal of positive selection. Population genetic analysis indicates that 614G increases in frequency relative to 614D in a manner consistent with a selective advantage. We do not find any indication that patients infected with the Spike 614G variant have higher COVID-19 mortality or clinical severity, but 614G is associated with higher viral load and younger age of patients. Significant differences in growth and size of 614G phylogenetic clusters indicate a need for continued study of this variant.

1 July 2012 in Immunity
Verified
Journal Article
Open access
MHMuzlifah Haniffa
Muzlifah Haniffa
ASAmanda Shin
Amanda Shin
VBVenetia Bigley
Venetia Bigley
NMNaomi McGovern
Naomi McGovern
PTPearline Teo
Pearline Teo
FGFlorent Ginhoux
Florent Ginhoux
Dendritic cell (DC)-mediated cross-presentation of exogenous antigens acquired in the periphery is critical for the initiation of CD8(+) T cell responses. Several DC subsets are described in human tissues but migratory cross-presenting DCs have not been isolated, despite their potential importance in immunity to pathogens, vaccines, and tumors and tolerance to self. Here, we identified a CD141(hi) DC present in human interstitial dermis, liver, and lung that was distinct from the majority of CD1c(+) and CD14(+) tissue DCs and superior at cross-presenting soluble antigens. Cutaneous CD141(hi) DCs were closely related to blood CD141(+) DCs, and migratory counterparts were found among skin-draining lymph node DCs. Comparative transcriptomic analysis with mouse showed tissue DC subsets to be conserved between species and permitted close alignment of human and mouse DC subsets. These studies inform the rational design of targeted immunotherapies and facilitate translation of mouse functional DC biology to the human setting.

1 September 1986 in Cell
Verified
Journal Article
Closed access
MFMark B. Feinberg
Mark B. Feinberg
RJRuth F. Jarrett
Ruth F. Jarrett
AAAnna Aldovini
Anna Aldovini
RGRobert C. Gallo
Robert C. Gallo
FWFlossie Wong-Staal
Flossie Wong-Staal

1 March 2021 in Cell
Verified
Journal Article
Open access
ETEmma Thomson
Emma Thomson
LRLaura E. Rosen
Laura E. Rosen
JSJames G. Shepherd
James G. Shepherd
RSRoberto Spreafico
Roberto Spreafico
AFAna da Silva Filipe
Ana da Silva Filipe
GSGyorgy Snell
Gyorgy Snell
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S, and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild-type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the FDA, and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.

20 May 1999 in Oncogene
Verified
Journal Article
Closed access
ECEric Cabannes
Eric Cabannes
GKGulfaraz Khan
Gulfaraz Khan
FAFabienne Aillet
Fabienne Aillet
RJRuth F Jarrett
Ruth F Jarrett
RHRonald T Hay
Ronald T Hay

29 October 2021 in Science
Verified
Journal Article
Open access
AWArthur Wickenhagen
Arthur Wickenhagen
ESElena Sugrue
Elena Sugrue
SLSpyros Lytras
Spyros Lytras
SKSrikeerthana Kuchi
Srikeerthana Kuchi
Marko NoerenbergMarko Noerenberg
Marko Noerenberg
SWSam Wilson
Sam Wilson
The bat connection: The heterogeneity of COVID-19 makes it challenging to predict the course of infection in an individual. Upon virus infection, interferons (IFNs) generate the initial signals for cellular defenses. Knowing that defects in IFN signaling are associated with more severe COVID-19, Wickenhagen et al . used IFN-stimulated gene expression screening on human lung cells from which they identified a gene for 2′-5′-oligoadenylate synthetase 1 (OAS1) (see the Perspective by Schoggins). OAS1 stimulates RNase L to inhibit the virus with a surprising degree of specificity, targeting the membranous organelles in which it replicates. In most mammals, OAS1 is attached to membranes by a prenyl group. However, billions of humans do not have the prenylated OAS1 haplotype, including many experiencing severe COVID-19. The same is true for horseshoe bats, prolific sources of betacoronaviruses, because of an ancient retrotransposition event. —CA